Layer, Chiang, et al. Genome Biology
Leerink Swann Lowers Estimate for Illumina's Q1 Revenues, EPS
The investment firm lowered its estimates from levels predicted last week to reflect lost consumables sales on its older next-gen sequencing platforms and softer microarray consumables sales sequentially.
New to GenomeWeb? Register here quickly for free access.